Market Research Industry Reports

Athenex Inc (ATNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Athenex Inc (Athenex), formerly Kinex Pharmaceuticals LLC is a drug manufacturing and distributing company that distributes therapies for cancer diseases and supportive therapies. The company offers drug discovery, drug formulation and clinical development. It offers products such as ointment formulation, oral formulation, oral absorption platform and symptom therapeutics. Athenex also provides transmucosal drug, active ingredients and intermediates, pharmaceutical and specialty chemicals, and in-vitro diagnostic devices. The company has its presence in the US and China. It partners with pharmaceutical companies, universities and research institutions located across Guangzhou, China; Dunedin, New Zealand; Taipei, Taiwan; Seoul, South Korea; and Guatemala City, Guatemala. Athenex is headquartered in Buffalo, New York, the US.

Athenex Inc (ATNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.




Athenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Athenex Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Athenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Athenex Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Athenex Inc, Medical Devices Deals, 2012 to YTD 2018 12
Athenex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Athenex Inc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Athenex Acquires 14 ANDAs and Inventory for Certain APIs from Amphastar Pharma 15
Venture Financing 16
Athenex Raises USD20 Million in Venture Debt Financing 16
Athenex Raises USD38 Million in Financing 17
Kinex Pharma Raises USD10 Million in Venture Financing 18
Kinex Pharma Raises USD74.4 Million in Venture Financing 19
Kinex Pharma Raises US$0.3 Million In Venture Financing 20
QuaDPharma Raises US$1 Million In Venture Financing 21
Kinex Pharma Raises Funds In First Tranche Of Financing Round 22
Kinex Pharma Raises US$5 Million In Venture Financing 23
Partnerships 24
Athenex Enters into Agreement with Imuna Pharm 24
Athenex Enters into Partnership with Eli Lilly and Company 25
Athenex to Form Joint Venture with SunGen Pharma 26
Athenex Enters into Agreement with Fort Schuyler Management 27
Licensing Agreements 28
Almirall to Enter into Licensing Agreement with Athenex for KX2-391 28
Athenex to Enter into Licensing Agreement with Gland Pharma 29
Athenex to Enter into Licensing Agreement with Gland Pharma 30
Kinex Pharma Enters into Licensing Agreement with Hong Kong Polytechnic University and McGill University 31
PharmaEssentia Amends Licensing Agreement with Athenex for Oraxol and Oratecan 32
Zenith Technology Enters into Licensing Agreement with Kinex Pharma for Oraxol and Oratecan 33
Xiangxue Pharma Enters into Licensing Agreement with Kinex Pharma for KX02 34
Kinex Pharma Expands Licensing Agreement With Hanmi Pharma 35
Equity Offering 37
Athenex Prices Public Offering of Shares for USD65.6 Million 37
Athenex Raises USD76 Million in IPO 39
Athenex Raises USD3.5 Million in Private Placement of Shares 41
Athenex Raises USD5 Million in Private Placement of Shares 42
Athenex Raises USD6.6 Million in Private Placement of Shares 43
Kinex Pharma Raises Funds through Private Placement of Shares 44
Athenex Raises USD4 Million in Private Placement of Shares 45
Athenex Raises USD6 Million in Private Placement of Series A Preferred Stock 46
Kinex Pharma Completes Private Placement Of Shares For US$40 Million 47
Acquisition 48
Athenex Acquires Comprehensive Drug Enterprises for USD15 Million 48
Athenex Acquires Polymed Therapeutics 49
Kinex Pharma Acquires QuaDPharma for USD5.5 Million 50
Athenex Inc - Key Competitors 51
Athenex Inc - Key Employees 52
Athenex Inc - Locations And Subsidiaries 53
Head Office 53
Other Locations & Subsidiaries 53
Recent Developments 54
Financial Announcements 54
Mar 26, 2018: Athenex Announces Fourth Quarter and Full-Year 2017 Results 54
Nov 09, 2017: Athenex Announces Third Quarter 2017 Results 56
Aug 14, 2017: Athenex Announces Second Quarter 2017 Results 59
Corporate Communications 62
Dec 01, 2017: Athenex Announces Planned Retirement of Chief Financial Officer Nick Riehle 62
Mar 01, 2017: Athenex announces the promotion of Jeffrey M. Yordon to the position of Chief Operating Officer 63
Feb 27, 2017: Athenex appoints veteran J. Nick Riehle as Chief Financial Officer 64
Government and Public Interest 65
Sep 11, 2017: Athenex Announces Grant Disbursement Agreement with New York State for Dunkirk Facility 65
Product News 66
Aug 10, 2017: Athenex Pharma Solutions, an Athenex, Company, Launches Three New Sterile Injectable Products from its 503(B) Facility 66
Aug 01, 2017: Athenex Announces Recent Product Launches in Commercial Business 67
Clinical Trials 68
Nov 28, 2017: Athenex Announces Acceptance of Phase II Data of KX2-391 for the Treatment of Actinic Keratosis for Presentation at the American Academy of Dermatology Meeting 68
Sep 25, 2017: Athenex Announces First Patient Recruitment in Phase III Clinical Trials for KX-01 Ointment for Actinic Keratosis 69
Mar 28, 2017: Athenex Announces the US FDA Allowance of the Investigational New Drug Application of Oratopo, A Combination of HM30181A and Oral Topotecan For the Treatment of Advanced Cancer 70
Other Significant Developments 71
Feb 13, 2018: Athenex Announces Recent Product Launches in 503B and Specialty Injectables Business Units 71
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72

List Of Tables

List of Tables
Athenex Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Athenex Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Athenex Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Athenex Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Athenex Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Athenex Inc, Medical Devices Deals, 2012 to YTD 2018 12
Athenex Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Athenex Acquires 14 ANDAs and Inventory for Certain APIs from Amphastar Pharma 15
Athenex Raises USD20 Million in Venture Debt Financing 16
Athenex Raises USD38 Million in Financing 17
Kinex Pharma Raises USD10 Million in Venture Financing 18
Kinex Pharma Raises USD74.4 Million in Venture Financing 19
Kinex Pharma Raises US$0.3 Million In Venture Financing 20
QuaDPharma Raises US$1 Million In Venture Financing 21
Kinex Pharma Raises Funds In First Tranche Of Financing Round 22
Kinex Pharma Raises US$5 Million In Venture Financing 23
Athenex Enters into Agreement with Imuna Pharm 24
Athenex Enters into Partnership with Eli Lilly and Company 25
Athenex to Form Joint Venture with SunGen Pharma 26
Athenex Enters into Agreement with Fort Schuyler Management 27
Almirall to Enter into Licensing Agreement with Athenex for KX2-391 28
Athenex to Enter into Licensing Agreement with Gland Pharma 29
Athenex to Enter into Licensing Agreement with Gland Pharma 30
Kinex Pharma Enters into Licensing Agreement with Hong Kong Polytechnic University and McGill University 31
PharmaEssentia Amends Licensing Agreement with Athenex for Oraxol and Oratecan 32
Zenith Technology Enters into Licensing Agreement with Kinex Pharma for Oraxol and Oratecan 33
Xiangxue Pharma Enters into Licensing Agreement with Kinex Pharma for KX02 34
Kinex Pharma Expands Licensing Agreement With Hanmi Pharma 35
Athenex Prices Public Offering of Shares for USD65.6 Million 37
Athenex Raises USD76 Million in IPO 39
Athenex Raises USD3.5 Million in Private Placement of Shares 41
Athenex Raises USD5 Million in Private Placement of Shares 42
Athenex Raises USD6.6 Million in Private Placement of Shares 43
Kinex Pharma Raises Funds through Private Placement of Shares 44
Athenex Raises USD4 Million in Private Placement of Shares 45
Athenex Raises USD6 Million in Private Placement of Series A Preferred Stock 46
Kinex Pharma Completes Private Placement Of Shares For US$40 Million 47
Athenex Acquires Comprehensive Drug Enterprises for USD15 Million 48
Athenex Acquires Polymed Therapeutics 49
Kinex Pharma Acquires QuaDPharma for USD5.5 Million 50
Athenex Inc, Key Competitors 51
Athenex Inc, Key Employees 52
Athenex Inc, Subsidiaries 53

List Of Figures

List of Figures
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Cancer Research Technology Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Cancer Research Technology Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Athenex Inc (ATNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Athenex Inc (Athenex), formerly Kinex Pharmaceuticals LLC is a drug manufacturing and distributing company that distributes therapies for cancer diseases and supportive therapies. The company offers drug discovery, drug formulation

USD 250View Report

Athenex Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

Athenex Inc (Athenex), formerly Kinex Pharmaceuticals LLC is a drug manufacturing and distributing company that distributes therapies for cancer diseases and supportive therapies. The company offers drug discovery, drug formulation

USD 250View Report

Athenex Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

Athenex Inc (Athenex), formerly Kinex Pharmaceuticals LLC is a drug manufacturing and distributing company that distributes therapies for cancer diseases and supportive therapies. The company offers drug discovery, drug formulation

USD 250View Report

Athenex Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Athenex Inc (Athenex), formerly Kinex Pharmaceuticals LLC is a drug manufacturing and distributing company that distributes therapies for cancer diseases and supportive therapies. The company offers drug discovery, drug formulation

USD 250View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Apr 2018
No. of Pages :72
Country :United States of America
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube